|
|
||||||||||||||||||
|
|
||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Questions? Please consult our answers to frequently asked questions at http://www.ebioscience.com/faq. DescriptionThe MD-1 antibody reacts with human, rhesus, cynomolgus and baboon interferon-gamma (IFN-γ), the signature Th1 cytokine, which is produced mainly by activated T cells, NK cells and B cells. IFN-γ is a dimeric protein. IFN-γ has antiviral and antiparasitic activities and also inhibits the proliferation of normal and transformed cells. Applications ReportedFor research use only, not for diagnostic or therapeutic use. The MD-1 antibody has been reported for use in intracellular staining and flow cytometric analysis, cytokine neutralization, immunohistochemical staining, ELISA Capture, and ELISPOT Capture. Fluorochrome conjugated 4S.B3 antibody is recommended for use in intracellular staining and flow cytometry. (Please use Functional Grade Purified MD-1 antibody, cat. 16-7317, in functional assays.) Applications TestedThe MD-1 antibody has been tested as the capture antibody in a sandwich ELISA for analysis of human interferon-γ (IFN-γ) in combination with the biotinylated 4S.B3 (13-7319) antibody for detection and recombinant human IFN-γ (14-8319) as the standard. A suitable range of concentrations of this antibody for ELISA capture is 1-4 µg/ml. A standard curve consisting of doubling dilutions of the recombinant standard over the range of 1000 pg/ml - 8 pg/ml should be included in each ELISA plate. The FG Purified format of the MD-1 antibody has been tested as the capture antibody in an ELISPOT assay (in conjunction with the biotinylated 4S.B3 antibody) and for neutralization of IFN-γ biological activity. A suitable range of concentrations of this antibody for ELISPOT capture is 1-4 µg/ml. For in vitro neutralization, the MD-1 antibody at 30 ug/ml has been found to neutralize by 50% the effect of 1 ng/ml human IFN-γ. A more potent neutralizing antibody is clone NIB42. References
Van der Meide, P.H., et al. 1985. J. Immuno. Meth. 79: 293. Yazdanbakhsh, M., et al. 1993. Eur. J. Immuno. 23: 3312. Besouw, N.M., et al. 1994. J. Med. Primatol. 23: 42. Van der Meide, P.H., et al. 1995. J. Med. Primatol. 24: 271. Hilkens, C. M. U., et al. 1996. J. Immunol. 156: 1722. Related ProductsCat. 16-4714 Functional Grade Purified Mouse IgG1, K Isotype Control Cat. 14-7318 Affinity Purified anti-human IFNg (Interferon-gamma, IFN-g) (clone NIB42) Cat. 16-7318 Functional Grade Purified anti-human IFNg (Interferon-gamma, IFN-g) (clone NIB42) Cat. 11-7319 FITC anti-human IFNg (Interferon-gamma, IFN-g) (clone 4S.B3) Cat. 12-7319 PE anti-human IFNg (Interferon-gamma, IFN-g) (clone 4S.B3) Cat. 13-7319 Biotin anti-human IFNg (Interferon-gamma, IFN-g) (clone 4S.B3) Cat. 14-7319 Affinity Purified anti-human IFNg (Interferon-gamma, IFN-g) (clone 4S.B3) Cat. 17-7319 APC anti-human IFNg (Interferon-gamma, IFN-g) (clone 4S.B3) Cat. 14-8319 Recombinant Human IFNg (Interferon-gamma, IFN-g) |
|||||||||||||||||||||||||||||||||||||||||||
![]() |
![]() |
|
Copyright © 2000-2008 eBioscience, Inc. Product For Research Use Only: Not for further distribution without written consent. |